

SUBSTANCE USE *Stewardship*

OHCA is proactively engaged in efforts to combat drug abuse. For more information about the opioid epidemic in Oklahoma, Medication Assisted Treatment, and a list of available treatment centers, visit okimready.org or okhca.org/opg.

Medication Assisted Treatment (MAT) Changes

Prior authorization for MAT is not required on preferred products. Per Section 1262 of the Consolidated Appropriations Act, 2023, providers are no longer required to have a DEAX number to prescribe MAT. Specific prior authorization criteria may be viewed at okhca.org/MAT.



Pregnant Members

Members who are pregnant may receive single ingredient buprenorphine tablets.

Morphine Milligram Equivalent and MAT

OHCA is committed to reducing opioid use disorder and overdoses. Medications for MAT will continue to be exempt from opioid morphine milligram equivalent (MME) limit implementation.

No Prior Authorization Required

- Buprenorphine/naloxone SL tablets - GENERIC ONLY
- Vivitrol® (naltrexone injection)

Prior Authorization Required

- Bunavail® (buprenorphine/naloxone buccal films)
- Zubsolv® (buprenorphine/naloxone SL tablets)
- Suboxone® (buprenorphine/ naloxone SL tablets and films) (brand)
- Buprenorphine/ naloxone SL films (generic)
- Subutex® (buprenorphine SL tablets)
- Probuphine® (buprenorphine implant)
- Lucemyra® (lofexidine)
- Sublocade® (buprenorphine ER injection)

Naloxone Companion

Naloxone, the opioid overdose antidote, should be prescribed with all MAT prescriptions. Providers are encouraged to co-prescribe this lifesaving drug to all at-risk patients. Additionally, members may now receive naloxone without seeing a physician by visiting an OHCA-contracted pharmacy. Pharmacists may now write a prescription for and dispense naloxone pursuant to a collaborative agreement.

Check Before You Write

Per Oklahoma law (HB 1948) providers should check the prescription monitoring program every time before prescribing MAT.